Hikma Pharmaceuticals (OTCMKTS:HKMPF) Sees Unusually-High Trading Volume - What's Next?

Key Points

• Hikma Pharmaceuticals experienced a 69% increase in trading volume on Monday, with approximately 2,223 shares exchanged, boosting its stock price from $24.36 to $24.50.
• BNP Paribas initiated coverage with an "outperform" rating for Hikma Pharmaceuticals, contributing to an average analyst rating of "Buy" for the stock.
• The company’s current ratio is 1.24, indicating adequate liquidity to meet its short-term obligations, with a low debt-to-equity ratio of 0.33.

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - Get Free Report) shares saw unusually-strong trading volume on Monday . Approximately 2,223 shares traded hands during mid-day trading, an increase of 69% from the previous session's volume of 1,312 shares.The stock last traded at $24.50 and had previously closed at $24.36.

Wall Street Analyst Weigh In

Separately, BNP Paribas initiated coverage on Hikma Pharmaceuticals in a research report on Tuesday, May 13th. They issued an "outperform" rating for the company. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy".

Hikma Pharmaceuticals Stock Performance

The company has a quick ratio of 0.72, a current ratio of 1.24 and a debt-to-equity ratio of 0.33. The stock has a fifty day moving average price of $26.48 and a 200-day moving average price of $26.82.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.